Can Hydralazine Be Reduced from TID to BID in a Patient with Low-Normal Blood Pressure?
Yes, hydralazine can be reduced from three times daily (TID) to twice daily (BID) dosing in a patient with low-normal blood pressure, as BID dosing has been shown to provide adequate 24-hour blood pressure control and is supported by both FDA labeling and clinical evidence.
Rationale for BID Dosing
The FDA-approved labeling for hydralazine 1 recommends starting at 10 mg four times daily, increasing to 25 mg four times daily, then 50 mg four times daily for maintenance. However, the label explicitly states that "individual titration is essential to ensure the lowest possible therapeutic dose" when combining with other antihypertensives, which is critical in your patient with low-normal BP.
Multiple clinical studies demonstrate that BID dosing provides equivalent blood pressure control to more frequent dosing:
A randomized controlled trial in 20 hypertensive patients found no significant differences in blood pressure control between conventional hydralazine given twice daily versus four times daily 2. The study specifically noted that "there is no need to administer hydralazine more than twice daily."
Another double-blind crossover study in 20 patients showed no statistically significant differences in BP or pulse rate between QID, BID conventional, and BID slow-release formulations 3. Mean BP differences were minimal (3.2 mmHg systolic, 0.5 mmHg diastolic).
A study in 23 patients with primary hypertension confirmed that blood pressure control achieved with multiple daily doses was maintained with once or twice daily administration of the same total daily dose 4.
Practical Approach to Dose Reduction
Given your patient's low-normal BP on 25 mg TID (75 mg total daily), I recommend the following algorithm:
Reduce to 25 mg BID (50 mg total daily) rather than maintaining the same total daily dose
- This provides both reduced frequency AND reduced total daily dose
- Addresses the low-normal BP concern while maintaining therapeutic effect
Monitor blood pressure closely for 1-2 weeks:
- Home BP monitoring is preferable to office readings
- Check BP at peak effect (2-4 hours post-dose) and trough (just before next dose)
- Target BP should remain <130/80 mmHg per current guidelines 5
If BP remains controlled, continue BID dosing
- If BP rises above target, consider increasing to 37.5 mg BID or 50 mg BID before returning to TID
Important Caveats
Acetylator status matters but shouldn't prevent BID dosing: Fast acetylators metabolize hydralazine more rapidly 6, 7, but studies show BID dosing works in both fast and slow acetylators 2, 3. The dose-response study found D50 values of 0.87 mg/kg for slow acetylators and 1.68 mg/kg for fast acetylators 6.
Watch for rebound effects: The FDA label warns that hydralazine's "hyperdynamic circulation" can cause reflex tachycardia 1. If your patient is not on a beta-blocker, monitor heart rate closely during dose reduction.
Consider the indication: If hydralazine is being used for heart failure with reduced ejection fraction (HFrEF) in combination with isosorbide dinitrate, the guideline-recommended dosing is TID 8. However, for hypertension alone, BID dosing is appropriate.
Avoid excessive BP lowering: With low-normal BP, the risk of symptomatic hypotension, particularly orthostatic hypotension, increases 1. The 2025 ACC/AHA guidelines emphasize that BP targets should be "as low as reasonably achievable" when treatment is poorly tolerated 5.
Bottom Line
Reduce to hydralazine 25 mg BID (or even 37.5 mg BID if using slow-release formulation) with close BP monitoring. This approach is evidence-based, reduces pill burden, improves adherence, and addresses the low-normal BP concern while maintaining therapeutic efficacy. The reduction in both frequency and total daily dose is justified given the patient's current BP status.